A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles médecine/sciences Year : 2012

A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor

Nouvelle thérapie antiangiogénique indépendante du VEGF qui cible le récepteur CD160

Domains

Life Sciences [q-bio] Immunology
Fichier principal
Vignette du fichier
medsci2012281p37.pdf (122.6 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

TABIASCO Julie  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-02168009

Submitted on : Friday, June 28, 2019-1:02:48 PM

Last modification on : Monday, March 27, 2023-9:34:26 AM

Download

Dates and versions

inserm-02168009 , version 1 (28-06-2019)

Identifiers

Cite

Philippe Le Bouteiller, Julie Tabiasco, Jérôme Giustiniani, Armand Bensussan. A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor. médecine/sciences, 2012, 28 (1), pp.37-38. ⟨10.1051/medsci/2012281013⟩. ⟨inserm-02168009⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-PARIS7 CNRS UP-SANTE INFINITY UNIV-UT3 UT3-TOULOUSEINP
56 View
58 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More